Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy.

To study the efficacy of fluconazole against chronic disseminated candidiasis (hepatosplenic candidiasis) in patients with leukemia in whom amphotericin B treatment had failed.
Retrospective analysis of patients with chronic disseminated candidiasis treated with fluconazole on a compassionate investigational new drug protocol.
Twenty consecutive patients received 100 to 400 mg of fluconazole per day for a median of 30 weeks. All had either failed to respond to treatment with more than 2 g of amphotericin B or had serious amphotericin B-related toxicities.
Fourteen of 16 evaluable patients (88%) responded. Responses were observed in seven of nine patients in whom adequate doses of amphotericin B had failed and in all seven patients who had amphotericin B-related toxicities. In 12 patients, cytotoxic chemotherapy was continued without flare of the infection. Fluconazole was well tolerated with rare side effects. Aspergillus superinfection developed in three patients and contributed to the death of two of them.
Fluconazole is a safe and effective agent with significant activity against chronic disseminated candidiasis.
AuthorsE Anaissie, G P Bodey, H Kantarjian, C David, K Barnett, E Bow, R Defelice, N Downs, T File, G Karam
JournalThe American journal of medicine (Am J Med) Vol. 91 Issue 2 Pg. 142-50 (Aug 1991) ISSN: 0002-9343 [Print] UNITED STATES
PMID1867240 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Amphotericin B
  • Fluconazole
  • Adult
  • Aged
  • Amphotericin B (adverse effects, therapeutic use)
  • Candidiasis (drug therapy)
  • Child, Preschool
  • Chronic Disease
  • Female
  • Fluconazole (therapeutic use)
  • Humans
  • Leukemia, Myeloid, Acute (complications)
  • Liver Diseases (drug therapy, microbiology)
  • Male
  • Middle Aged
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (complications)
  • Remission Induction
  • Retrospective Studies
  • Splenic Diseases (drug therapy, microbiology)
  • Superinfection

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: